BRPI0811223A2 - Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica. - Google Patents
Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica.Info
- Publication number
- BRPI0811223A2 BRPI0811223A2 BRPI0811223-1A2A BRPI0811223A BRPI0811223A2 BR PI0811223 A2 BRPI0811223 A2 BR PI0811223A2 BR PI0811223 A BRPI0811223 A BR PI0811223A BR PI0811223 A2 BRPI0811223 A2 BR PI0811223A2
- Authority
- BR
- Brazil
- Prior art keywords
- fluorokinoline
- ameliorating
- inflammation
- modulating
- eye
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94315407P | 2007-06-11 | 2007-06-11 | |
| PCT/US2008/064336 WO2008154136A1 (en) | 2007-06-11 | 2008-05-21 | Compositions and methods for modulating inflammation using fluoroquinolones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0811223A2 true BRPI0811223A2 (pt) | 2014-10-29 |
Family
ID=39673477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0811223-1A2A BRPI0811223A2 (pt) | 2007-06-11 | 2008-05-21 | Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080306038A1 (pt) |
| EP (1) | EP2170342A1 (pt) |
| JP (1) | JP2010529133A (pt) |
| KR (1) | KR20100021444A (pt) |
| CN (1) | CN101678032A (pt) |
| AU (1) | AU2008262118A1 (pt) |
| BR (1) | BRPI0811223A2 (pt) |
| CA (1) | CA2686833A1 (pt) |
| MX (1) | MX2009013123A (pt) |
| TW (1) | TW200904429A (pt) |
| WO (1) | WO2008154136A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0819175A2 (pt) * | 2007-11-05 | 2015-05-05 | Bausch & Lomb | Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidade |
| CN102114020B (zh) * | 2009-12-30 | 2016-04-20 | 北京德众万全医药科技有限公司 | 一种含有贝西沙星或其盐的药用组合物及其制备方法 |
| WO2015114666A2 (en) | 2014-01-29 | 2015-08-06 | Vyome Biosciences Pvt. Ltd. | Treatments for resistant acne |
| CN119587555B (zh) * | 2024-12-17 | 2025-12-19 | 江汉大学 | 依碳氯替泼诺作为nlrp3炎症小体激活抑制剂的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2613139B2 (ja) * | 1990-07-19 | 1997-05-21 | エスエス製薬 株式会社 | キノロンカルボン酸誘導体 |
| US6685958B2 (en) * | 2001-04-25 | 2004-02-03 | Insite Vision Incorporated | Quinolone carboxylic acid compositions and related methods of treatment |
| WO2003035066A1 (en) * | 2001-10-23 | 2003-05-01 | Celltech R & D Limited | 2-aminoquinolone derivatives for use as impdh inhibitors |
| WO2004097410A1 (en) * | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Screening methods for cataractogenic risk |
-
2008
- 2008-05-21 MX MX2009013123A patent/MX2009013123A/es not_active Application Discontinuation
- 2008-05-21 AU AU2008262118A patent/AU2008262118A1/en not_active Abandoned
- 2008-05-21 CN CN200880019421A patent/CN101678032A/zh active Pending
- 2008-05-21 EP EP08769550A patent/EP2170342A1/en not_active Withdrawn
- 2008-05-21 CA CA002686833A patent/CA2686833A1/en not_active Abandoned
- 2008-05-21 US US12/124,578 patent/US20080306038A1/en not_active Abandoned
- 2008-05-21 KR KR1020097025828A patent/KR20100021444A/ko not_active Ceased
- 2008-05-21 BR BRPI0811223-1A2A patent/BRPI0811223A2/pt not_active IP Right Cessation
- 2008-05-21 JP JP2010511245A patent/JP2010529133A/ja not_active Withdrawn
- 2008-05-21 WO PCT/US2008/064336 patent/WO2008154136A1/en not_active Ceased
- 2008-05-28 TW TW097119746A patent/TW200904429A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008262118A1 (en) | 2008-12-18 |
| EP2170342A1 (en) | 2010-04-07 |
| WO2008154136A1 (en) | 2008-12-18 |
| KR20100021444A (ko) | 2010-02-24 |
| CN101678032A (zh) | 2010-03-24 |
| TW200904429A (en) | 2009-02-01 |
| JP2010529133A (ja) | 2010-08-26 |
| CA2686833A1 (en) | 2008-12-18 |
| MX2009013123A (es) | 2010-01-15 |
| US20080306038A1 (en) | 2008-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| AU2015205914B2 (en) | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BRPI0909749A2 (pt) | uso de fotoiniciador para fabrico de medicamento para tratamento do ceratocone, da ectasia e fortalecimento da córnea | |
| EP2407171A3 (en) | Compositions and methods for the treatment of ophthalmic disease | |
| EP3606570B8 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
| EA201300272A1 (ru) | Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
| WO2010141648A3 (en) | Artificial tears and therapeutic uses | |
| BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
| DE602007004615D1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
| EA200870396A1 (ru) | Лечение аллергических заболеваний глаз | |
| WO2008054639A3 (en) | Use of a catechin or polyphenol to treat ocular diseases and infection | |
| WO2009040420A3 (en) | Use of a monoterpene to increase tissue repair | |
| WO2011084366A3 (en) | Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions | |
| ATE535257T1 (de) | Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin | |
| MX342183B (es) | Suspension oftalmica para uso ocular. | |
| WO2008136034A3 (en) | Ophthalmic compositions for the treatment of ocular hypertension and glaucoma | |
| BR112017015387A2 (pt) | composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra | |
| BR112012015386B8 (pt) | composição oftálmica tópica | |
| BRPI0510778A (pt) | composição farmacêutica, processo para a preparação da mesma, método para o tratamento de rinite, e, uso de uma composição | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| BRPI1008103A2 (pt) | " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos " |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |